Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title: Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations

Status Recruiting

Clinical Trial Summary

This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients. Giving U-13C-glucose during surgery may allow doctors to trace the metabolic activity of pancreatic cancer in research experiments done in the laboratory. These experiments may help researchers understand how cancer cells manage their nutrients when compared to normal pancreatic cells.

Clinical Trial Description

PRIMARY OBJECTIVE:

I. To describe and discover new insights into the glucose, tricarboxylic acid (TCA) cycle, amino acid, and lipid metabolic dependencies of pancreatic ductal adenocarcinoma (PDAC) via liquid chromatography-mass spectrometry (LC-MS) analysis of in vivo uniformly-labeled [13C]glucose (U-13C-glucose) labeled pancreatic cancer biopsies.

OUTLINE:

Patients receive uniformly-labeled [13C]glucose intravenously (IV) over 10 minutes and then over up to 120 minutes until time of biopsy. Patients then undergo surgery and biopsy per standard of care. ;

Related Conditions & MeSH terms

• Pancreatic Ductal Adenocarcinoma

• NCT number: NCT05296421
• Study type: Interventional
• Source: Rutgers, The State University of New Jersey
• Contact: Howard Hochster, MD
• Phone: 732-235-5912
• Email: howard.hochster@rutgers.edu
• Status: Recruiting
• Phase: N/A
• Start date: March 14, 2022
• Completion date: July 1, 2026